


In the Specification

Applicant presents replacement paragraphs below indicating the changes with insertions indicated by underlining and deletions indicated by strikeouts.

Please replace paragraph 1 beginning at page 32, line 2 with the amended paragraph as follows:

Methods and products for stimulating hematopoietic hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both *in vivo* and *in vitro*. The methods involve administering an agent of Formula I:



Formula I

wherein m is an integer between 0 and 10, inclusive; A and A₁ are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A₁ and C, and between A₁ and N are peptide bonds; and each X₁ and X₂ is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. A particularly preferred agent that is useful in practicing the invention is a ValBoroPro.

Please add the new paragraph after line 1 on page 1 as follows:

Related Applications

This application is a continuation application of prior U.S. patent application No. 09/304,199, filed May 3, 1999, entitled Hematopoietic Stimulation, now issued as U.S. Patent 6,300,314 B1 the entire contents of which are incorporated herein by reference and which claims

priority under 35 U.S.C. § 119(e) to U.S. provisional application serial number 60/084,128 filed May 4, 1998.

Please replace paragraph 1 beginning at page 10, line 2 with the amended paragraph as follows:

According to another aspect of the invention, the agents useful herein can be applied at doses below those which were described in the prior art. In particular, it has been discovered unexpectedly that the agents of the invention can be administered in doses less than 1 mg/kg body weight per day. In particular, the agents of the invention have been used successfully at levels of 0.1 mg/kg body weight per day, which is ~~10-orders~~ one order of magnitude below the teachings of the prior art. As will be readily recognized by those of ordinary skill in the art, this has advantages in that less material is required for treatment, thereby lessening any risk of side effects. Likewise, this has advantages in connection with the cost of manufacture of the drug products of the invention.

In the Drawings

A Request for Approval of Proposed Drawing Corrections is enclosed along with revised Figure 9.

Applicant presents replacement Figure 9 which includes the amended changes.

The word "Hematopoesis" in Figure 9 is misspelled. The correct spelling should be "Hematopoiesis"

Attached is one replacement sheet for Figure 9 and one annotated sheet showing the changes.